Navigation Links
Decision Resources to Publish Reports That Include Market Analysis and a Forecast through 2022 for the Hepatitis C Virus and Hospital-Treated Bacterial Infections Drug Markets
Date:12/18/2013

BURLINGTON, Mass., Dec. 18, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, will soon publish a comprehensive market analysis and a forecast though 2022 for both the hepatitis C virus (HCV) drug market and the hospital-treated bacterial infections drug market.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

Key findings from the upcoming Pharmacor advisory service entitled Hepatitis C Virus reveal that Gilead's Sovaldi—the first direct acting antiviral (DAA) approved for the treatment of HCV as part of an IFN-free regimen—represents a safe, convenient (all-oral), and highly efficacious option for genotype-1, -2 and -3 patients, particularly those who are unable or unwilling to undergo treatment with IFN-based regimens. Sovaldi, as well as Janssen/Medivir's Olysio/Sovriad, were both recently approved by the U.S. Food and Drug Administration for the treatment of both treatment-naive and treatment-experienced HCV patients.

The findings also reveal that the HCV pipeline is dynamic and competitive, owing to the large commercial potential that is well recognized by pharmaceutical developers. Agents in late-stage development—such as protease inhibitors (AbbVie's ritonavir-boosted ABT-450, Boehringer-Ingelheim's faldaprevir, Merck's MK-5172), polymerase inhibitors (AbbVie's ABT-333, Bristol-Myers Squibb's BMS-791325, Boehringer-Ingelheim's deleobuvir) and NS5A inhibitors (Bristol-Myers Squibb's daclatasvir, Gilead's ledipasvir and GS-5816, AbbVie's ABT-267 and Merck's MK-8742), among others—are expected to drive dramatic growth of the HCV market through 2022. These DAAs are being evaluated in all-oral, IFN-free regimens consisting of 2-3 DAAs in combinations with and without ribavirin.

Key findings from the upcoming Pharmacor advisory service entitled Hospital-Treated Infections reveal that two beta-lactam/beta-lactamase inhibitors—Cubist's CXA-201 and Forest/AstraZeneca's CAZ-AVI—are poised for commercial success, owing to their activity against extended-spectrum beta-lactamase (ESBL)-producing gram-negative pathogens. Both therapies are expected to gain traction as infections due to ESBL producers have become more prevalent across all major markets, especially among urinary tract infections (UTIs), complicated intra-abdominal infections (cIAIs) and nosocomial pneumonia.

However, because of avibactam's expanded activity against Klebsiella pneumoniae carbapenemases (KPCs) and class C ESBLs, which the currently marketed beta-lactamase inhibitor tazobactam lacks, Decision Resources expects greater uptake of CAZ-AVI in indications where these drug-resistance mechanisms are prevalent, specifically UTIs and cIAIs. Conversely, given CXA-201's activity against a range of drug-resistant Pseudomonas aeruginosa isolates—including those resistant to the carbapenem  imipenem/cilastatin (Merck's Primaxin/Tienam, generics)—this agent is expected to be reserved for serious gram-negative infections due to this pathogen.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. National Decision Support Company offers free access to ACR Select
2. Pharmspective Launches Affordable Care Act eLearning for Healthcare Decision-Makers
3. Pharmaceutical Industry Turning to Emerging Market Research Tools to Better Understand Consumer Decision-Making
4. Decision on State Exchanges Will Aid Patient Access to Medications
5. Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.
6. Beyond the Headlines: What the FDA Decisions on Extended-release and Long-Acting Opioids Mean for People With Pain
7. Strategic Insights Series Now Available from Decision Resources
8. Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
9. CorMedix Reports Receipt of European Patent Office Decision to Allow Prosl Patent to Proceed in European Union
10. Hamilton Regional Laboratory Medicine Program Announces Decision to Acquire COPANs WASPLab, the Next Generation Full Laboratory Automation and Digital Bacteriology System
11. Health Decisions CEO Michael Rosenberg, MD, MPH, Offers Insights into Adaptive and Risk-Based Monitoring in the Journal of Clinical Research Best Practices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
Breaking Medicine News(10 mins):